Literature DB >> 27214361

Immune tolerance induction in haemophiliacs with inhibitor to FVIII: high- or low-dose programme.

W Kucharski1, R Scharf1, T Nowak1.   

Abstract

In 1993-94, 15 high responders were treated in our centre according to the Malmo protocol which was modified as follows: serial plasmapheresis was performed instead of extracorporeal adsorbtion to protein A for reducing inhibitor levels and, after the bolus dose to neutralize the inhibitor, factor VIII concentrate was administered by a continuous infusion. Thus, this regimen included continuous infusion of factor VIII(FVIII) for 1-4 weeks, iv cyclophosphamide for 2 days and orally for 8-10 days, and intravenous immunoglobulin (IVIG) from the fourth day for 5 days. All patients had been qualified for the treatment when the antibody level was < 15 BU mL(-1) . Tolerance was induced in 10 patients (66.6% very good and good results). The treatment failed in five cases in which, due to a high inhibitor level, it was not possible to maintain a measurable factor VIII:C concentration throughout the whole period of infusion. We compared these results with results of our low-dose regimen: 25 IU FVIII kg(-1) b.w. twice a week (1985-89, 11 high responders). The modified Malmo Protocol is much shorter than the low-dose programme and this is a method of first choice in patients undergoing surgery in the near future.

Entities:  

Keywords:  FVIII inhibitor; continuous infusion of FVIII; haemophilia A; immune tolerance

Year:  1996        PMID: 27214361     DOI: 10.1111/j.1365-2516.1996.tb00141.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

Review 1.  Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.

Authors:  Abha H Athale; Maura Marcucci; Alfonso Iorio
Journal:  Cochrane Database Syst Rev       Date:  2014-04-24

2.  Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.

Authors:  Zahra Rezaieyazdi; Hassan Mansouritorghabeh
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

3.  Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol.

Authors:  Ricardo Mesquita Camelo; Daniel Gonçalves Chaves; Luciana Werneck Zuccherato; Suely Meireles Rezende
Journal:  PLoS One       Date:  2021-08-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.